Includes prescription and medication
The group lawsuit representing people harmed by Mounjaro and other GLP-1 drugs has grown by 486 cases between August and September of 2025
By cutting back on frequent in-person weigh-ins, organizations can keep pace with growing patient volumes without sacrificing quality of care
This highlights the need for ongoing research to clarify the potential risks associated with GLP-1 agonists and thyroid health
If you notice any swelling, severe redness, or burning sensations, discontinue use immediately
Agell L, Hernandez S, de Muga S, Lorente JA, Juanpere N, Esgueva R et al